Research Article |
Corresponding author: Reem A. Issa ( r.issa@ammanu.edu.jo ) Corresponding author: Mahmoud Abu-Samak ( m_abusamak@asu.edu.jo ) Academic editor: Rumiana Simeonova
© 2024 Raheeq Khairy Abdullah, Reem A. Issa, Mahmoud Abu-Samak, Beisan A. Mohammad, Manal A. Abbas, Shady Helmi Awwad.
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Citation:
Abdullah RK, Issa RA, Abu-Samak M, Mohammad BA, Abbas MA, Awwad SH (2024) Nephroprotective effects of Equisetum ramosissimum L. extract in streptozotocin-induced diabetic rats. Pharmacia 71: 1-11. https://doi.org/10.3897/pharmacia.71.e113659
|
Diabetes is a widespread health issue that impacts people all over the globe. The Equisetum ramosissimum L. plant has numerous traditional uses and pharmacological properties, including antidiabetic effects.The objective of this study was to thoroughly examine the advantages of incorporating extracts from the aerial components of E. ramosissimum to control diabetic nephropathy. The phytochemical constituents of E. ramosissimum extract were explored using phytochemical and HPLC analysis, focusing on phenols and flavonoid content. The effect of plant extract was evaluated on different kidney function parameters linked to diabetic nephropathy (fasting blood glucose, creatinine, uric acid, and urea) in streptozotocin induced-diabetic rats. Histopathological changes in the liver were also examined. The results showed methanol and ethanol extracts of E. ramosissimum have a total content of phenols (equivalent to gallic acid, 7.62 and 8.97 mg/g) and flavonoids (equivalent to quercetin, 8.87 and 12.86 mg/g), respectively. After conducting the UHPLC-MS/MS analysis, it was found that both the methanol and ethanol extracts contained isoferulic acid, ISO-Orientin, myristic acid, linoelaidic acid, rutin, and 3-Glu-7-Rha quercetin. Additionally, isoferulic acid, myristic acid, linoelaidic acid, rutin, and 3-Glu-7-Rha quercetin were present in the extracts. The ethanol extract of E. ramosissimum significantly impacted STZ-induced diabetic mice by reducing their fasting blood glucose levels, and their creatinine and urea levels (P < 0.005). In conclusion, E. ramosissimum ethanol extract has shown potential effects to counteract some diabetes consequences on kidney function. Therefore, further studies are required to investigate its effect on other diabetes-related complications.
Equisetum ramosissimum, diabetes, nephroprotective, kidney functions, phenols, flavonoids
According to the WHO report (
The persistent complications of diabetes are broadly partitioned into microvascular and macrovascular complications, including diabetic nephropathy, which influences 20–30% of diabetic patients, with oxidative harm playing a critical part in its pathogenesis (Al-Waili et al. 2017).
Herbal and dietary supplements that are rich in flavonoids can potentially decrease the occurrence of diabetes. This effect is achieved by lowering blood sugar levels and offering other benefits that aid in the treatment and prevention of complications related to diabetes (
Some flavonoid compounds have shown preventive impacts on diabetic complications, such as hesperidin, naringenin, quercetin kaempferol, puerarin, and myricetin (Gandhi et al. 2020). The therapeutic effects of numerous components of flavonoids on diabetic nephropathy have been illustrated in vitro and in vivo studies, particularly apigenin, baicalein, and catechin, through anti-oxidation effects (
The study species Equisetum ramosissimum is called “horsetail” (
Extracts from various Equisetum species were utilized in recent studies on diabetic rats. The results indicate that E. arvense exhibits high levels of phenolic and flavonoid compounds with potent antioxidant properties, making it a promising addition to diabetes therapy (
The main goal of this research was to explore the potential health benefits of different extract preparations from E. ramosissimum to prevent diabetes-related nephropathy. Multiple extracts of E. ramosissimum were created and analyzed to determine their antioxidant properties, concentration of phenols, and flavonoid content. The plant extract with optimal content of phytocomponents was investigated for its effect on different kidney function parameters linked to diabetes nephropathy, as it is considered a major complication of diabetes.
For this study, the E. ramosissimum species was sourced from the Mujib reserve in Jordan. The plant species was authenticated by a knowledgeable botanist from the Royal Society for the Conservation of Nature (RSCN) with voucher number (E. ramosissimum 5/7/2017). The aerial components of the E. ramosissimum were cleaned, dried, and ground into smaller pieces using a blender.
A range of extracts from the plant under study was obtained using the maceration method. The extracts were created by mixing 500 mL of either methanol or ethanol with 50 g of dry plant material at room temperature (25.0 °C) for 24 hours. Then, the resulting mixture was filtered with filter paper. Afterwards, the extracts were completely dehydrated using a rotary evaporator (R-300, Buchi, USA), at 60 °C and 90 rpm. Finally, each dried extract was accurately weighed to determine the extraction yield.
The total phenol content was determined through the Folin-Ciocalteu technique, as outlined in Sadeghi et al.’s publication (2015). A combination of 5 mL of plant extract solution (or gallic acid), Folin-Ciocalteu reagent, and 5% aqueous Na2CO3 was prepared. After a 30-minute incubation period, the phenolic concentration was measured calorimetrically using Spectrophotometer (Hitachi U-1800, UK) at 765 nm. The total phenolics (mg/mL) amount was subsequently calculated as the gallic acid equivalent.
After dissolving each extracted sample in 2 mL of DMSO and up to 50 ml of acetonitrile, they were centrifuged at 4000 rpm for 2.0 min. Then, 3.0 µL of each sample containing 1.0 ml was injected into the autosampler.
A Bruker Daltonik (Bremen, Germany) Impact II electrospray ionization quadrupole time of flight (ESI-Q-TOF) system equipped with a Bruker Daltonik Elute Ultra-Performance Liquid Chromatography (UPLC) system (Bremen, Germany) were thoroughly utilized to test specific compounds against an integrated library. Chromatography was employed to separate the compounds, and they were analyzed for m/z and the retention time using highly precise Bruker TOF MS and standards.
Chromatographic separation was performed with the utmost precision using the Bruker solo 2.0 C-18 UHPLC column (100 mm × 2.1 mm × 2.0 m) at a consistently reliable flow rate of 0.51 mL/min and a stable column temperature of 40 °C. The solvents used, a mixture of water containing 0.05% formic acid (A) and acetonitrile (B), were carefully selected to optimize the results. B’s method was skillfully employed for a 35-minute analysis with gradient elution (80–95%), ensuring the accuracy and efficiency of the process.
Wistar rats weighing 150–200 grams and aged 70 days received a regular diet and had unrestricted water access from Hammoudeh business in Amman, Jordan. The experiments on rats were conducted in accordance with the Declaration of Helsinki. Before the experiment, the rats were acclimated to the animal housing conditions for ten days, including a temperature range of 21–23 °C and a 12-hour light-dark cycle. The Institutional Committee on Ethics of Animal Experimentation approved the procedure. All procedures were performed in accordance with international regulations for the care and use of laboratory animals. Ethical approval for the study was obtained by the Institutional Review Board at Applied Science Private University, Amman, Jordan, Approval Number: 2021-PHA-40.
The rats were given two doses of freshly dissolved streptozotocin (STZ, Sigma, USA). through intraperitoneal (IP) administration. A total of 55 mg/kg of STZ was given in citrate buffer (0.01 M, pH 4). The first dose was 30 mg/kg, followed by a second dose of 25 mg/kg on the third day after 48 hours. After each STZ dose, the rats were returned to their cages and provided unrestricted food and drink access (5% dextrose to prevent severe hypoglycemia). Control rats were given citrate buffer.
After 72 hours of administering STZ, the rats were confirmed to have diabetes (STZ-DM: STZ-induced diabetes). A commercial glucose kit measured their blood glucose levels Qualigens Diagnostics – AccuChek- (ROCHE, TD-4277, Augsburg, Germany). The test of the blood sample from the rat’s tail was applied twice on each test-strip lot. If the fasting blood glucose (FBG) level was 250 mg/dL or higher (
Two more samples were collected and analyzed alongside the blood droplets to confirm and monitor STZ-DM as follows:
The dried plant extract was dissolved in distilled water at 100 or 150 mg/ml concentrations to create fresh ethanol E. ramosissimum extract stock solutions. Each was given orally to rats through an intragastric tube, with a dose of 200 or 300 mg/kg BW, like a prior research study (Carneiro 2013). The E. ramosissimum extract treatments began on the third day after STZ injection, and the experiment was conducted for three weeks on the same days after diabetes was induced.
A detailed investigation examined the potential benefits of E. ramosissimum extract in preventing diabetes and protecting against kidney damage. The study involved forty-two rats, divided into seven groups of six animals, each as follows:
The rats were not fed the night before they were euthanized on the 21st day of the experiment. Blood samples were collected before and after the experiment to produce serum, which was then analyzed using liquicolor-HUMAN kits to measure the levels of FBG, creatinine (Cr), uric acid (UA), and urea (U).
The kidney slices, fixed in formalin and embedded in paraffin wax, were stained using Hematoxylin and Eosin (H & E) at a thickness of 4 micrometers. The sections were thoroughly examined under a Leica microscope (The Life Sciences companies at Danaher Corporation (“Danaher”), Germany) and captured using a Leica MC 170 HD camera utilizing LAS EZ software.
Version 27.0 of the Statistical Package for the Social Sciences (SPSS) for Windows, developed in Chicago, IL, USA, was utilized to perform the statistical analysis.
The one-way ANOVA test was used to identify any significant differences in the average values of each parameter among different experimental groups. The post hoc multiple comparisons with Dunnett’s Multiple Comparisons tests were used to analyze any meaningful variations in mean values between the experimental and control groups.
The study aimed to thoroughly examine the potential impact of FBG as a predictor of diabetes mellitus and Cr, U, and UA as predictors of diabetes nephropathy from the beginning to the end of the trial. Using a stepwise approach to multiple linear regression, researchers determined the factors that played a crucial role in the relationships between diabetes and diabetic nephropathy across various research groups.
The extraction yield was computed using % w/w dry weight. Based on the data, it was found that ethanol produced the highest output at 3.42%, followed closely by methanol at 2.78%.
Based on the analysis of total phenol content, it has been determined that the methanol and ethanol extracts contain 7.62 and 8.97 mg/g, equivalent to gallic acid, respectively.
Upon evaluating their total flavonoid content, it has been determined that the methanol and ethanol extracts possess 8.87 and 12.86 mg/g of quercetin, respectively.
Identification of the phytocomponents present in the methanol and ethanol extracts of E. ramosissimum was made possible using UHPLC/MS-MS. Tables
Phytochemicals detected in E. ramosissimum methanol extract using UHPLC/MS-MS.
Phytochemicals detected in E. ramosissimum ethanol extract using UHPLC/ MS-MS.
During the study, all groups, except the control group, showed a considerable reduction in their average body weight at the beginning and end of the research. This fact is undeniably supported by the P-value of 0.05, as shown in Table
Changes of BW at baseline and the end of experiment in all study groups.
Body weight (g) | ||||
---|---|---|---|---|
Group (n=6) | Baseline | End of the study | Change (%) | P a |
C | 178.3±12.2 | 190.8±10.7 | 12.50 (7.01%) | < 0.001 |
SDM | 210±22.6 | 142.5±24.7 | -67.50 (-32.14%) | < 0.001 |
SDMET | 200±16.1 | 166.7±8.2 | -33.33 (-16.67%) | 0.06 |
Q2 | 205±5.5 | 192.5±5.2 | -12.5 (-6.01%) | < 0.001 |
SDMQ2 | 221.7±15.1 | 152.5±32.1 | -69.17 (-31.20%) | 0.002 |
Q3 | 187.5±10.4 | 175±10.5 | -12.5 (-6.67%) | < 0.001 |
SDMQ3 | 213.3±15.4 | 167.5±26.2 | -45.83 (-21.5%) | 0.001 |
F | 6.367 | 5.419 | ||
P b | < 0.001 | |||
P c | < 0.001 |
Based on the results shown in Table
Changes of FBG at baseline and the end of the experiment in all study groups.
Fasting Blood Glucose (FBG) (mg/dl) | ||||
---|---|---|---|---|
Group (n=6) | Baseline | End of the study | Change (%) | P a |
C | 93.90±5.04 | 93.78±3.84 | -0.06 (-0.06%) | 0.955 |
SDM | 487.8±40.4 | 501.7±64.6 | 43.83 (8.99%) | 0.104 |
SDMET | 326±85.8 | 81.2±27.4 | -244.78 (-75.08%) | < 0.001 |
Q2 | 91±8.2 | 90.9±9.8 | -0.13 (-0.14%) | 0.979 |
SDMQ2 | 423±115.7 | 132.7±55.6 | -290.3 (-68.7) | |
Q3 | 93.4±14.5 | 101.1±8.2 | 7.72 (8.27%) | 0.369 |
SDMQ3 | 259.2±74.7 | 155.93±78.1 | -103.27 (-39.8) | 0.002 |
F | 37.93 | 66.714 | ||
P b | < 0.001 | |||
P c | < 0.001 |
As shown in Table
Changes in urea (U) at baseline and the end of the experiment in all study groups.
Urea (U) (ng/ml) | ||||
---|---|---|---|---|
Group (n=6) | Baseline | Follow-up | Change (%) | P a |
C | 37.7±4.04 | 37.5±5.14 | -0.2 (-0.53%) | 0.91 |
SDM | 42.6±5.2 | 43.1±0.2 | 0.5 (1.17%) | 0.71 |
SDMET | 43±9.3 | 53.1±9.5 | 10.02 (23.3%) | 0.012 |
Q2 | 40.3±2.6 | 34±4 | -6.23 (-15.46%) | 0.007 |
SDMQ2 | 43±9.34 | 32.5±4.9 | -10.6 (-24.65%) | 0.013 |
Q3 | 39.8±1.9 | 29.9±3.4 | -9.93 (-24.25%) | 0.003 |
SDMQ3 | 30.6±5.2 | 30.6±11 | 0.00 (0%) | 0.995 |
F | 4.6 | 9.2 | ||
P b | 0.002 | |||
P c | < 0.001 |
Fig.
Final Mean values of Urea serum levels at the end of the study. Abbreviations: C = non-diabetic control group, SDM = STZ-induced diabetic rats, SDMET = STZ-induced diabetic rat + metformin (50 mg/kg/day), Q2 = Low dose extract (200 mg/kg/day), SDMQ2 = STZ-induced diabetic rats + Low dose extract (200 mg/kg/day), Q3 =: High dose extract (300 mg/kg/day), SDMQ3 = STZ-induced diabetic rats + High dose extract (300 mg/kg/day). NOTE: Results are represented as Mean±SD (n=6 for each group). * p < 0.05, ** p < 0.01, and *** p < 0.001 when compared with the SDM; • p < 0.05, •• p < 0.01, and •••p < 0.001 when compared with the SDMT (Dunnett’s Multiple Comparisons Test).
As presented in Table
Changes in mean creatinine (Cr) levels at baseline and the end of the experiment in all study groups.
Creatinine (Cr) (ng/ml) | ||||
---|---|---|---|---|
Group (n=6) | Baseline | Follow-up | Change (%) | P a |
C | 0.44±0.05 | 0.43±0.08 | -0.08 (-18.18%) | 0.94 |
SDM | 0.51±0.07 | 0.62±0.07 | 0.11 (21.57%) | 0.05 |
SDMET | 0.44±0.05 | 0.55±0.05 | 0.11 (25%) | 0.035 |
Q2 | 0.43±0.04 | 0.50±0.02 | 0.08 (18.60%) | 0.004 |
SDMQ2 | 0.62±0.07 | 0.48±0.06 | -0.13 (-20.97%) | 0.001 |
Q3 | 0.44±0.02 | 0.43±0.04 | -0.02 (-4.54%) | 0.413 |
SDMQ3 | 0.51±0.07 | 0.42±.0.12 | -0.09 (-17.65%) | 0.278 |
F | 8.589 | 7.301 | ||
P b | < 0.001 | |||
P c | < 0.001 |
Final Mean values of Urea serum levels at the end of the study. Abbreviations: C = non-diabetic control group, SDM = STZ induced diabetic rats, SDMET = STZ-induced diabetic rat + metformin (50 mg/kg/day), Q2 = Low dose extract (200 mg/kg/day), SDMQ2 = STZ-induced diabetic rats + Low dose extract (200 mg/kg/day), Q3 =: High dose extract (300 mg/kg/day), SDMQ3 = STZ-induced diabetic rats+ High dose extract (300 mg/kg/day). NOTE: Results are represented as Mean±SD (n=6 for each group). * p < 0.05, ** p < 0.01, and *** p < 0.001 when compared with the SDM; • p < 0.05, •• p < 0.01, and •••p < 0.001 when compared with the SDMT (Dunnett’s Multiple Comparisons Test).
Table
Changes in Uric acid (UA) at baseline and the end of the experiment in all study groups.
Uric Acid (UA) (ng/ml) | ||||
---|---|---|---|---|
Group (n=6) | Baseline | Follow-up | Change (%) | P a |
C | 1.17±0.13 | 1.34±0.18 | 0.17 (14.52%) | 0.64 |
SDM | 1.67±0.11 | 1.86±0.37 | 0.19 (11.38%) | 0.352 |
SDMET | 1.17±0.13 | 1.18±0.39 | 0.01 (0.85%) | 0.948 |
Q2 | 1.11±0.09 | 1.51± 0.51 | 0.41 (36.94%) | 0.126 |
SDMQ2 | 1.86±0.37 | 1.72±0.26 | -0.14 (-7.53%) | 0.234 |
Q3 | 1.20±0.16 | 1.21±0.25 | 0.01 (0.003%) | 0.948 |
SDMQ3 | 1.67±0.11 | 1.00±0.24 | -0.67 (-40.12%) | 0.003 |
F | 17.980 | 5.858 | ||
P b | < 0.001 | |||
P c | < 0.001 |
The findings from Table
The multivariate associations between the experiment variables using stepwise regression at the end of the experiment (3 weeks).
Dependent variable | Study group | Univariate effect estimate | Coefficient | ||||
---|---|---|---|---|---|---|---|
B | F | R | R2 | P-value | |||
Cr | SDMQ2 | FBG | 0.002 | 13.134 | 0.876 | 0.767 | 0.022 |
BW | 0.001 | 26.723 | 0.973 | 0.947 | 0.012 | ||
UA | SDMQ2 | BW | -0.007 | 7.901 | 0.815b | 0.664 | 0.048 |
SDMQ3 | U | 0.02 | 21.964 | 0.920 | 0.846 | 0.009 |
The stepwise regression analysis showed significant associations between IDVs such as FBG, BW, and Cr levels. In addition, the influence of BW on UA levels was also observed. During follow-up, the multiple linear regression model explained a considerable 95% and 66.4% of the variation in Cr and UA, respectively. The SDMQ3 showed a robust reciprocal association between U and UA levels, with a whopping 85% of the variation in UA or U levels at follow-up fully explained by the model.
The control group’s rat liver tissue samples underwent light microscopy analysis to reveal the typical histological architecture of the hepatocytes, central vein, sinusoids, hepatic triads, and Kupffer cells. However, diabetic rats’ liver tissue samples exhibited necrotic hepatocytes with lymphocyte infiltration, disorganized sinusoids, and dilated central veins. It is important to note that compared to metformin-treated rats, diabetic rats treated with the extract showed significantly reduced necrosis in the liver, as seen in Fig.
Under light microscopy, the kidney sections of control rats displayed regular Bowman’s capsule, proximal tubules, and distal tubules. However, STZ-treated diabetic rats showed renal abnormalities, including glomerular tuft atrophy, renal tubule degeneration, and an increase in Bowman’s gap size, as well as hemorrhage and renal blood vessel congestion. Despite most administered Bowman’s capsules to diabetic rats with typical kidney damage, some distal tubules exhibited widening. Regrettably, metformin did not provide any protection against STZ-induced kidney damage, as shown in Fig.
Kidney sections (A) control. B, C. STZ-treated diabetic-rat showing atrophy of glomerular tuft (white arrow in B arrow), increase in the Bowman’s space area and degeneration of renal tubules (Black arrow in C) associated with severe hemorrhage and congestion of renal blood vessels; D. Extract-treated rats. Renal tubules (Black arrow), Bowman’s capsule (white arrow); E, F. Metformin-treated rats. H & E stain.
The Jordanian herbal treatments for diabetes were thoroughly examined by
According to preclinical studies, it is evident that E. ramosissimum ethanol extract (
This study has shown that E. ramosissimum extract has similar effects to metformin in reducing FBG, U and Cr levels in diabetic and normal rats. It is noteworthy that previous studies have identified several Equisetum plant species that protect against adverse impacts on renal function in diabetic rats (
In SDMQ2 group, significant reduction (P< 0.05) in the means serum U and Cr levels were observed, while means serum UA levels was reduced in SDMQ3 only. These findings may point to potential powerful antioxidant activity for the extracts, but higher doses as in SDMQ3 study group might have an adverse or toxic effects (
Furthermore, the same group (SDMQ2) practically showed similar effect to that observed in diabetic -metformin treated group (SDM). Accordingly, in the term of the potential anti-DN effects for E. ramosissimum extract observed in SDMQ2 group , its bioactive compounds are likely to have therapeutic outcomes . Based on the stepwise regression findings in these experiments, the bioactive compound in the extract is expected to act peripherally rather than centrally. in this context, it has shown that the intervention of E. myriochaetum extract significantly reduced FBG levels without significant changes in the insulin levels in type 2 diabetic patients (
The antidiabetic and nephron protective effect for E. ramosissimum observed in the present study can be explained by various phytochemicals, such as phenols and flavonoids, with pronounced antioxidant effects (
In addition, the HPLC analysis for the extract revealed the presence of ferulic acid isomers (isoferulic acid). This compound is well known to prevent the synthesis of advanced glycation end products, which is responsible for altering other proteins and generating oxidizing intermediates, causing oxidative stress in vascular cells and other tissues. As a result, this phytocomponent may play an essential preventive role in age-related illnesses and diabetic complications, including nephropathy (
The fatty acids, linolelaidic and myristic acids were observed in the prepared extracts. Compositions of fatty acids in four Equisetum sp. (E. arvense, E. palustre, E. ramosissimum, and E. telmateia) revealed that linoleic acid was the predominant fatty acid in these species. In contrast, myristic acid was the second major fatty acid (
Accordingly, the antidiabetic and nephron protective effects observed in STZ-induced diabetic rats treated with the ethanolic extract of E. ramosissimum can be considered a novel finding. A significant reducing effect was observed on FBG, Cr, and U levels in STZ-induced diabetic rats.. This expectation was raised from the significant association between BW and FBG with UA and Cr levels in the STZ-diabetic rats treated with different doses of the extract.
The high content of phenols and flavonoids in the ethanol extracts of E. ramosissimum is likely to be responsible for the proposed effect via antioxidant activity. Therefore, further research is required to investigate its mechanism of action on the molecular level.
The authors thank Mr Salim for his technical assistance and Mr Anas Sabarini for preparing the specimen and verifying the plant. The Applied Science Private University/Faculty of Pharmacy in Amman, Jordan, is acknowledged for providing the necessary infrastructure and research facilities. Furthermore, the Deanship of Graduate Studies at Al-Ahliyya Amman University in Amman, Jordan, has funded this work.